NCT03447808View on ClinicalTrials.gov

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

December 1, 2025

Study Completion Date

April 15, 2026

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

Daratumumab

Given IV

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Jennifer Woyach

OTHER